Paris, France (ots) -
- Data presented at ATTD by Sanofi will focus on the company's integrated portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery and contributions to advancing diabetes research -
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its comprehensive portfolio of innovative diabetes solutions will be presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France (February 27 - March 2). The annual ATTD conference is the leading diabetes technology meeting in Europe, and Sanofi will showcase its commitment to advancing therapeutic solutions and diabetes care technology aimed at improving patient outcomes.
Abstracts include the latest clinical data on the early benefits of Lantus® (insulin glargine), the accuracy, reliability and ease-of- use of the BGStar® and iBGStar® blood glucose meters, and the SoloSTAR® insulin delivery device. The study design of the biggest multi-national register of diabetes research in the young, TEENS, will also be featured.
In addition, Sanofi will sponsor a plenary satellite symposium at ATTD titled "Technology: Contributing to Diabetes Management Today and Tomorrow" which will provide an overview of current and future treatments, tools and projects to facilitate clinical decision making and empower patients to take control of their diabetes. The session will conclude with a presentation on the artificial pancreas in children.
"Today, effective diabetes management is increasingly a matter of simplifying day-to-day routines for people living with the condition. This means we need comprehensive approaches to diabetes care based on technological advances," said Pierre Chancel, Senior Vice President, Sanofi, Global Diabetes. "Sanofi's diabetes teams are dedicated to providing innovative and integrated technological solutions combined with patient support services that help people with diabetes effectively manage their disease while living the lives they want to live."
Highlights of the data being presented are as follows (abstracts are available on the ATTD website www2.kenes.com/attd):
iNewTrend study: "Effect of Glucose Monitoring with Smartphone Integration on Metabolic Control and Compliance in Type 1 Diabetes (iNew Trend): Study Design" When: Session 26: Oral Presentations, Saturday 2 March, 12:20 - 12:30pm CET Presenter: V. Cherubini, Polytechnic University of Marche, Ancona, Italy Where: CNIT Paris La Defense Exhibition Hall, Hall III
EARLY LANTUS study: "Early Onset of Glycaemic Improvements after Insulin Initiation with Insulin Glargine in Patients with Type 2 Diabetes Mellitus Uncontrolled with OADs: Pooled Analysis from Clinical Trials" When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET Presenter: D.R. Owens, Institute of Molecular and Experimental Medicine, Cardiff, UK Where: CNIT Paris La Defense Exhibition Hall, Poster Area
LANTUS survey: "Survey on Physician Experiences in Initiation of Insulin in Type 2 Diabetes Patients: Preliminary Results for Insulin Glargine" When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET Presenter: R. Roussel, Diabetology, Endocrinology and Nutrition Department, Paris, France Where: CNIT Paris La Defense Exhibition Hall, Poster Area
TEENS study: "International Evaluation of Diabetes Management, Glycaemic Control and Quality of Life in Youth with Type 1 Diabetes: the TEENS Study" When: E-Poster Session 4, Friday 1 March, 10:00am CET Presenter: L. Laffel, Harvard Medical School, Boston, USA Where: CNIT Paris La Defense Exhibition Hall, Exhibition Area, Poster Station 2
BGStar® and iBGStar® abstracts include:
"Assessment of Ascorbic Acid and Acetaminophen Interference on the Performance of Blood Glucose Meters for Patient Self-Testing" When: Poster Session, Thursday 28 February, 8:00am - 17:00pm CET Presenter: A. Pfützner, IKFE - Institute for Clinical Research and Development, Mainz, Germany Where: CNIT Paris La Defense Exhibition Hall, Poster Area
"Laboratory Study for Evaluation of the Influence of Temperature and Humidity on Blood Glucose Measurements with BGStar and iBGStar" When: Poster Session, Thursday 28 February, 8:00am - 17:00pm CET Presenter: A. Pfützner, IKFE - Institute for Clinical Research and Development, Mainz, Germany Where: CNIT Paris La Defense Exhibition Hall, Poster Area
"Performance of Current Blood Glucose Meters in Compliance with the New Draft Clinical ISO15197: 2010 Accuracy Criteria" When: Poster Session, Thursday 28 February, 8:00am - 17:00pm CET Presenter: A. Pfützner, IKFE - Institute for Clinical Research and Development, Mainz, Germany Where: CNIT Paris La Defense Exhibition Hall, Poster Area
"Impact of Strip Filling on the Performance of Glucose Meters for Patient Self-Testing" When: Poster Session, Thursday 28 February, 8:00am - 17:00pm CET Presenter: A. Pfützner, IKFE - Institute for Clinical Research and Development, Mainz, Germany Where: CNIT Paris La Defense Exhibition Hall, Poster Area
SoloSTAR® abstracts include:
"Field Study on Rotational Speeds and Angles used by Patients Dialing a Dose on Four Different Disposable Insulin Pens" When: E-Poster Session 1, Thursday 28 February, 10:05am CET Presenter: A. Friedrichs, LWS Risk Management Consult GmbH, Brannenburg, Germany Where: CNIT Paris La Defense Exhibition Hall, Exhibition Area, Poster Station 1
"Torque for Dose Dialing of Four Disposable Insulin Pens SoloSTAR, FlexTouch, FlexPen, and KwikPen: Results of a Laboratory Study" When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET Presenter: A. Friedrichs, LWS Risk Management Consult GmbH, Brannenburg, Germany Where: CNIT Paris La Defense Exhibition Hall, Poster Area
Sanofi-Sponsored Plenary Satellite Symposium:
"Technology: Contributing to Diabetes Management Today and Tomorrow" When: Session 8: Plenary Satellite Symposium, Thursday 28 February, 15:00 - 16:30pm CET Chairman: L. Heinemann, Profil Institute for Metabolic Research, Neuss, Germany Where: CNIT Paris La Defense Exhibition Hall, Hall I
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate, with more than 371 million people worldwide living with the condition today.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including intelligent blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
This press release contains forward-looking statements. Forward- looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward- looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
 International Diabetes Federation. IDF Diabetes Atlas, 5th edn. Brussels, Belgium: International Diabetes Federation, 2011. http://www.idf.org/diabetesatlas (Accessed: February 14, 2013 - 17:30 pm)
Global Diabetes Division Diagnostics and Delivery Solutions Milena Saleh Mobile: +49 173 68 96 040 E-mail: Milena.Saleh@sanofi.com